Your session is about to expire
← Back to Search
Talabostat + Pembrolizumab for Cancer
Study Summary
This trial studies talabostat and pembrolizumab as a treatment for advanced solid cancers. Talabostat may stop cancer cell growth by blocking enzymes needed for cell growth. Pembrolizumab is an immunotherapy that may help the body's immune system attack the cancer. Giving talabostat and pembrolizumab may help control the disease.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My liver enzymes are within the acceptable range.My advanced cancer has worsened after treatment with PD1/PDL1 inhibitors.My advanced cancer is resistant or intolerant to standard treatments, except PD1 or PD-L1 inhibitors.I have HIV or hepatitis B/C, but my viral load is undetectable.My kidney function, measured by creatinine levels, is within the normal range.My brain cancer has not spread, or if it has, it's under control without steroids.You have taken a new and untested cancer medication within the 14 days before starting this study.I have advanced cancer and may or may not have been treated with PD1/PDL1 antibodies. If treated, my cancer has returned.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.I am able to get out of my bed or chair and move around.I am not pregnant, use effective birth control, or am not of childbearing potential.I agree to use barrier contraception and my partner will use additional birth control during and after the study.I am under 18 and weigh more than 40 kg.The doctor thinks you will live for at least 3 more months.I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.I have a stomach or intestine problem that affects how I absorb medicine.I do not have serious heart problems or uncontrolled high blood pressure.My doctor believes I have more than 3 months to live and I can care for myself.I haven't had radiation or cancer drugs within the last 14 days or 5 half-lives.I have advanced cancer and haven't been treated with PD1/PDL1 antibodies.My cancer can be measured by specific medical scans.I have another cancer, but it's either non-melanoma skin cancer, carcinoma in situ, or not requiring treatment.My hemoglobin is at least 8 g/dL and I haven't had a blood transfusion in the last week.I am currently taking gliptin medication.Side effects from my previous cancer treatment are mild, except for possible nerve pain or hair loss.You have a medical condition that increases your risk of experiencing harmful side effects, as determined by the investigator.I cannot swallow pills.
- Group 1: Treatment (talabostat, pembrolizumab)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are volunteers still needed for this research project?
"That is correct, the information available on clinicaltrials.gov does show that this study is still looking for research subjects. This trial was originally announced on March 19th 2020 and updated September 7th 2020. They are currently enrolling 15 individuals at a single location."
What other immunotherapy drugs have been trialed with Pembrolizumab?
"Pembrolizumab is being investigated in 1000 different clinical trials, 122 of which are Phase 3. There are many studies for Pembrolizumab located in Houston, Texas, but there are 36030 locations running trials for Pembrolizumab globally."
How many individuals are signing up to participate in this experiment?
"That is correct, the online clinicaltrials.gov registry currently shows that this study is open and recruiting patients. The listing indicates that the trial was first posted on March 19th, 2020 and updated September 7th, 2020. Currently, they are looking for 15 more participants across 1 location."
Is Pembrolizumab known to have negative side effects for patients?
"While there is some data supporting its safety, pembrolizumab did not yet receive a score of 3 because there is no efficacy data from clinical trials."
What are the benefits of Pembrolizumab?
"Oftentimes, Pembrolizumab is used to fight malignant neoplasms. However, this treatment has also been found effective in cases of unresectable melanoma, microsatellite instability high, and disease progression after chemotherapy."
Share this study with friends
Copy Link
Messenger